Prothena Surges After Parkinson's Drug Misses Primary Endpoint

Summary

• Prothena's stock surged 34% despite Prasinezumab missing its Phase IIb primary endpoint, as Roche continues to invest.
• Prothena's pipeline includes multiple clinically staged drugs, with partnerships with major pharma companies, offering high-risk/high-reward potential.
• Investors should be cautious due to Prothena's 61% stock decline in 2024, but meaningful clinical success could create a buying opportunity.
• Prothena is rated as a HOLD, with upcoming catalysts in Parkinson's and Alzheimer's diseases that could fuel significant price appreciation.

spawns/E+ via Getty Images

Prothena Corporation plc (NASDAQ:PRTA) is a clinically staged biopharmaceutical company specialized in neurodegenerative diseases and based in Dublin, Ireland. On Thursday, Prothena's partner Roche (OTCQX:RHHBY) announced that a Phase IIb

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.